How to buy Cochlear shares

Own Cochlear shares in just a few minutes.

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

Cochlear Limited is a medical devices business based in Australia. Cochlear shares (COH) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollars. Cochlear has a trailing 12-month revenue of around $1.3 billion. If you're looking to buy shares, check out the steps below.

How to buy shares in Cochlear

  1. Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
  3. Search for Cochlear. Find the share by name or ticker symbol: COH. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Cochlear reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At today's price, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
  6. Check in on your investment. Congratulations, you own a part of Cochlear. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Cochlear share price

Use our graph to track the performance of COH stocks over time.

Cochlear shares at a glance

Information last updated 2021-06-09.
52-week range$175.7264 - $237.94
50-day moving average $221.9914
200-day moving average $209.6997
Target price$184.4
PE ratio N/A
Dividend yield $1.15 (0.49%)
Earnings per share (TTM) $5.294

Compare share trading platforms

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
Name Product Standard brokerage fee Inactivity fee Markets
Superhero share trading
AUD $5
ASX shares, ETFs
Pay zero brokerage on all Australian ETFs.
Trade ASX stocks with a flat $5 commission fee and a low minimum investment of just $100.
ThinkMarkets Share Trading
AUD $8
ASX shares, ETFs
Limited offer: Get 5 free ASX trades when you open a new account with ThinkMarkets before June 30, 2021 (T&Cs apply).
Buy and sell CHESS sponsored ASX shares with $0 brokerage on your first 5 trades. Only $8 flat fee brokerage thereafter, plus enjoy free live stock price data on an easy to use mobile app.
Bell Direct Share Trading
AUD $15
ASX shares, mFunds, ETFs
⭐ Finder Exclusive: Get 5 free stock trades and unlimited ETF trades until July 31, 2021 when you join Bell Direct.
Bell Direct offers a one-second placement guarantee on market-to-limit ASX orders or your trade is free, plus enjoy extensive free research reports from top financial experts.
IG Share Trading
Finder Award
IG Share Trading
AUD $8 or 0.1%
$50 per quarter if you make fewer than three trades in that period
ASX shares, Global shares
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.
Saxo Capital Markets (Classic account)
AUD $6.99
ASX shares, Global shares, Forex, CFDs, Margin trading, Options trading, ETFs
Acess 19,000+ stocks on 37 exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.
CMC Markets Stockbroking
AUD $11 or 0.1%
ASX shares, Global shares, mFunds, ETFs
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 9,000 products, including shares, ETFs and managed funds, plus access up to 15 major global and Australian stock exchanges.
ANZ Share Investing
AUD 19.95
ASX shares, Global shares, Options trading, mFunds, ETFs, Warrants
Earn 1 Qantas Point per AU$3 spent on brokerage fees on certain instruments.
Access Morningstar reports, company announcements and and live pricing via ANZ’s share investing platform. Available for desktop and mobile.
Westpac Online Investing Account
AUD 19.95 or 0.11%
USD 63.50 per year on the global markets account
ASX shares, Global shares, Options trading, ETFs

Compare up to 4 providers

Is it a good time to buy Cochlear stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Cochlear price performance over time

Historical closes compared with the last close of A$228.85

1 week (2021-06-07) -0.59%
1 month (2021-05-14) 5.74%
3 months (2021-03-12) 12.07%
6 months (2020-12-14) 16.93%
1 year (2020-06-12) 19.52%
2 years (2019-06-14) 12.06%
3 years (2018-06-14) 20.57%
5 years (2016-06-14) 87.58%

Is Cochlear under- or over-valued?

Valuing Cochlear stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cochlear's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Cochlear's EBITDA

Cochlear's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $266.7 million.

The EBITDA is a measure of a Cochlear's overall financial performance and is widely used to measure a its profitability.

Cochlear financials

Revenue TTM $1.3 billion
Operating margin TTM 17.23%
Gross profit TTM $964.7 million
Return on assets TTM 7.04%
Return on equity TTM -13.06%
Profit margin -12.22%
Book value 24.974
Market capitalisation $15.5 billion

TTM: trailing 12 months

Cochlear's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Cochlear.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Cochlear's total ESG risk score

Total ESG risk: 24.39

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Cochlear's overall score of 24.39 (as at 12/31/2018) is nothing to write home about – landing it in it in the 45th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Cochlear is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Cochlear's environmental score

Environmental score: 3.73/100

Cochlear's environmental score of 3.73 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Cochlear is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Cochlear's social score

Social score: 14.34/100

Cochlear's social score of 14.34 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Cochlear is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Cochlear's governance score

Governance score: 10.32/100

Cochlear's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Cochlear is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Cochlear's controversy score

Controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Cochlear scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Cochlear has, for the most part, managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Cochlear Limited was last rated for ESG on: 2019-01-01.

Total ESG score 24.39
Total ESG percentile 44.88
Environmental score 3.73
Environmental score percentile 2
Social score 14.34
Social score percentile 2
Governance score 10.32
Governance score percentile 2
Level of controversy 2

Cochlear share dividends

We're not expecting Cochlear to pay a dividend over the next 12 months.

Cochlear share price volatility

Over the last 12 months, Cochlear's shares have ranged in value from as little as $175.7264 up to $237.94. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Cochlear's is 0.372. This would suggest that Cochlear's shares are less volatile than average (for this exchange).

Cochlear overview

Cochlear Limited provides implantable hearing solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers cochlear implants, including Nucleus 7, Nucleus 6, Nucleus CP802, and Kanso sound processors; and Baha bone conduction implants, such as Baha attract system, Baha connect system, Baha softband, Baha soundarc, Baha 5 sound processor, and Baha sound processor. It also provides Cochlear true wireless accessories comprising mini microphones, phone clips, and TV streamers; Nucleus water-safe accessories; and training and development services. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs comes with a higher risk of losing money rapidly due to leverage. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site
Not sure what platform to go with?
Take this quick quiz to find the right share trading platform